Navigation Links
Epic Sciences Announces Appointment of Dr. Murali Prahalad as President and CEO

SAN DIEGO, Aug. 22, 2013 /PRNewswire/ -- Epic Sciences, Inc. ("Epic"), a private biotech company that develops breakthrough cancer diagnostics, announced the appointment of Murali K. Prahalad, Ph.D. as president and CEO.  Dr. Prahalad was formerly vice president of Corporate Strategy at Life Technologies, where he helped shape the organic and inorganic investment priorities across Life Technologies' research tools, clinical diagnostic and applied market portfolios.


"Dr. Prahalad has extensive experience in creating and leading global strategies for life science research tools and diagnostics as well as building innovative teams and forging productive partnerships," said Kim Kamdar, Ph.D., partner at Domain Associates. "We welcome Dr. Prahalad at this significant time in Epic's growth as the company begins global development and commercialization of important new diagnostic tests for detecting cancer and personalizing and monitoring cancer treatments."

Epic develops new diagnostic tests that isolate and characterize circulating tumor cells (CTCs) to assess the aggressiveness of a patient's cancer and provide physicians tools to personalize and monitor treatments. CTCs are cells that escape from solid tumors and enter the bloodstream. A blood test that can accurately count CTCs in a patient's blood and profile biomarkers within those CTCs is easy to conduct frequently and can give essential, real-time information that enables the tailoring of treatments to a patient's specific cancer type.

"The team at Epic has quickly proven and developed a complete technology platform that can detect, quantify and molecularly characterize rare, circulating tumor cells. They have also developed significant partnerships with pharmaceutical companies, leading academic labs and research institutions to advance Epic's technology for companion diagnostics and new cancer detection tests," said Dr. Prahalad, president and CEO of Epic Sciences. "I look forward to working with the team and our partners to build a robust pipeline of new diagnostic tests that improve cancer detection and treatment for patients globally."

Dr. Prahalad was with Life Technologies since 2005, where he held multiple positions of increasing responsibility.  His experience at Life Technologies ranged from mergers and acquisitions to in-licensing and general management, where he led large businesses that spanned genomics to cell biology.  As a general manager, he had to grow revenue and profit by building stronger teams, driving innovation and managing operations for both consumable and instrument portfolios.

Portfolios of note and relevance to Epic included Molecular Probes®, transfection (Lipofectamine®), custom primers and research antibodies in addition to Life Technologies imaging instrumentation (FLoID®, TALI®, Countess®) and flow cytometry platforms (Attune®). Prior to Life Technologies, he was vice president of Business Development at Sequenom, Inc. In addition, Dr. Prahalad has held roles as a consultant at The Advisory Board Company and as an analyst at Gemini Consulting in Tokyo. He is also proficient and literate in several languages including Japanese, French and Kannada. Dr. Prahalad received a Ph.D. in biochemistry and molecular pharmacology and an M.S. in medical sciences from Harvard University, and he received his a B.S. with honors in cellular and molecular biology and economics from the University of Michigan. 

About Epic Sciences

Epic Sciences, Inc. is a privately held company that is developing new diagnostics to improve and personalize the treatment and management of cancer. Epic was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic has partnered with leading pharmaceutical companies, major cancer centers, the National Cancer Institute (NCI) and the National Institutes of Health (NIH), to advance this technology to improve clinical oncology and cancer therapeutic development. For more information, please visit

SOURCE Epic Sciences
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Evolving Market Access in the APAC Region, a new Xtalks Life Sciences Webinar
2. SeraCare Life Sciences Acquires KPL
3. Pharmaceutical Cold Supply Chain and Green Logistics, a New Xtalks Life Sciences Webinar
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
5. Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition
6. Charm Sciences, Inc. Announces Charm® FAST PHAGE Method Accepted by EPA for Detection of Coliphage in Ground Water
7. MD Biosciences Offers IL-23-Induced Psoriasis-Like Preclinical Model for Skin Inflammation
8. SeraCare Life Sciences Goes Live With SAP
9. Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology
10. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
11. Tech Employment Continues to Grow in July Despite Slowdown in Life Sciences
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... Program that includes over 2,000 technical presentations offered in symposia, oral sessions, ... and applied spectroscopy, covers a wide range of applications such as, but not ...
(Date:11/25/2015)... ANNAPOLIS, Md. , Nov. 25, 2015  PharmAthene, ... of Directors has adopted a stockholder rights plan (Rights ... its net operating loss carryforwards (NOLs) under Section 382 ... --> --> PharmAthene,s use of its ... an "ownership change" as defined in Section 382 of ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
(Date:11/24/2015)... 24, 2015  Asia-Pacific (APAC) holds the third-largest ... market. The trend of outsourcing to low-cost locations ... higher volume share for the region in the ... margins in the CRO industry will improve. ... ( ), finds that the market earned ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... In the present market scenario, security is ... industry verticals such as banking, healthcare, defense, electronic gadgets, ... for secure & simplified access control and growing rate ... of bank accounts, misuse of users, , and so ... laptops, and smartphones are expected to provide potential opportunities ...
Breaking Biology News(10 mins):